Sam studied chemistry at the University of Manchester (M Chem) and Oxford (DPhil, supervisor Prof. Tim Donohoe).
After leaving Oxford Sam moved back to the northwest to take a position as a Medicinal Chemist at AstraZeneca, Alderley Park where he worked for 8 years. While at AZ his design and synthetic contributions led to the discovery of a promising targeted anti-cancer agent AZD9291, that is currently undergoing phase 2 clinical trials in late stage lung cancer.
While working on earlier-stage projects Sam led AstraZeneca’s strategic activities for 2 Oncology target classes, and headed the chemistry evaluation of a screening platform leading to a multi-million dollar collaboration to find leads against undruggable targets.
In addition to this he worked to define screening strategies, conducting HTS work up and led hit-to-lead activities for 4 successful HI/LI projects against several target classes, including developing new analytical approaches to identify hit families and understand selectivity/SAR from HTS data.
He also spent a year working with cross-disciplinary ‘Campaign 1’ delivery teams, responsible for rapid synthesis of kg-scale batches to support late-stage discovery and pre-clinical studies across infection, diabetes and oncology projects, including doing some kg scale synthesis with his own hands.
Over 8 years Sam line-managed teams of up to 6 synthetic chemists including Graduates, PhDs and Post-Docs and led teams of up to 16 chemists in a matrix environment.
In his final role at AstraZeneca Sam was able to apply the broad understanding of drug discovery and biological processes he had developed a role by developing and evaluating both internal and external clinical opportunities in diverse disease areas. In particular this involved leading chemistry input on repositioning projects delivered through strategic collaborations, open innovation platforms and outsourcing.
Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Matthew Box, Butterworth, S., et al.: Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR). Journal of Medicinal Chemistry 2013 56, 7025-7048.
Butterworth, Sam; Finlay, Maurice Raymond Verschoyle; Ward, Richard Andrew; Kadambar, Vasantha Krishna; Chandrashekar, Reddy C.; Murugan, Andiappan; Redfearn, Heather Marie; Preparation of 2-(2,4,5-substituted-anilino)pyrimidine derivatives as EGFR modulators useful for treating cancer. WO 2013014448.
Carr G., Butterworth S., Walker, P., Reck F., Geng B., Pandarinathan L.: A multi-kilo scale synthesis of (R)-methyl 2-((1r,4R)-4-(tert-butoxycarbonylamino)cyclohexyl)-2-(2-nitrophenylsulfonamido) acetate. Synthesis (2012), 44(6), 875-880.
Donohoe, T. J., Wheelhouse, K. M. P., Lindsay-Scott, P. J., Churchill, G. H., Connolly, M. J., Butterworth, S., Glossop, P. A.: Osmium-Mediated Oxidative Cyclizations: A Study into the Range of Initiators That Facilitate Cyclization. Chemistry - An Asian Journal 2009, 4(8), 1237-1247.
Kaiser, J., van Esseveldt, B. C. J., Segers, M. J. A., van Delft, F. L., Smits, J. M. M., Butterworth, S., Rutjes, F. P. J. T.: Synthesis and aromatization of cyclic enediyne-containing amino acids. Organic & Biomolecular Chemistry 2009, 7(4), 695-705.
Donohoe, T. J., Harris, R. M., Butterworth, S., Burrows, J. N., Cowley, A., Parker, J. S.: New osmium-based reagent for the dihydroxylation of alkenes. Journal of Organic Chemistry 2006, 71(12), 4481-4489.
Donohoe, T. J., Butterworth, S.: Oxidative cyclization of diols derived from 1,5-dienes: Formation of enantiopure cis-tetrahydrofurans by using catalytic osmium tetroxide; formal synthesis of (+)-cis-solamin. Angewandte Chemie, International Edition 2005, 44(30), 4766-4768.
Donohoe, T. J., Butterworth, S.: A general oxidative cyclization of 1,5-dienes using catalytic osmium tetroxide. Angewandte Chemie, International Edition 2003, 42(8), 948-951